112 related articles for article (PubMed ID: 30450781)
1. Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infection.
Holmes JA; Carlton-Smith C; Kim AY; Dumas EO; Brown J; Gustafson JL; Lauer GM; Silva ST; Robidoux M; Kvistad D; Alatrakchi N; Tonnerre P; Cohen DE; Zhang H; Shulman NS; Chung RT
J Viral Hepat; 2019 Mar; 26(3):362-372. PubMed ID: 30450781
[TBL] [Abstract][Full Text] [Related]
2. IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR.
Carlton-Smith C; Holmes JA; Naggie S; Lidofsky A; Lauer GM; Kim AY; Chung RT;
J Viral Hepat; 2018 May; 25(5):465-472. PubMed ID: 29193564
[TBL] [Abstract][Full Text] [Related]
3. Dasabuvir (ABT333) for the treatment of chronic HCV genotype I: a new face of cure, an expert review.
Mantry PS; Pathak L
Expert Rev Anti Infect Ther; 2016; 14(2):157-65. PubMed ID: 26567871
[TBL] [Abstract][Full Text] [Related]
4. Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects.
Waring JF; Dumas EO; Abel S; Coakley E; Cohen DE; Davis JW; Podsadecki T; Dutta S
J Viral Hepat; 2016 Feb; 23(2):96-104. PubMed ID: 26436610
[TBL] [Abstract][Full Text] [Related]
5. Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα.
Serti E; Park H; Keane M; O'Keefe AC; Rivera E; Liang TJ; Ghany M; Rehermann B
Gut; 2017 Apr; 66(4):724-735. PubMed ID: 26733671
[TBL] [Abstract][Full Text] [Related]
6. Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin.
Petersen T; Lee YJ; Osinusi A; Amorosa VK; Wang C; Kang M; Matining R; Zhang X; Dou D; Umbleja T; Kottilil S; Peters MG
AIDS Res Hum Retroviruses; 2016 Jul; 32(7):660-7. PubMed ID: 26974581
[TBL] [Abstract][Full Text] [Related]
7. Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection.
Lau DT; Negash A; Chen J; Crochet N; Sinha M; Zhang Y; Guedj J; Holder S; Saito T; Lemon SM; Luxon BA; Perelson AS; Gale M
Gastroenterology; 2013 Feb; 144(2):402-413.e12. PubMed ID: 23123437
[TBL] [Abstract][Full Text] [Related]
8. Expression of TRIM22 mRNA in chronic hepatitis C patients treated with direct-acting antiviral drugs.
Naveed M; Ali A; Sheikh N; Rafique S; Idrees M
APMIS; 2020 Apr; 128(4):326-334. PubMed ID: 31863490
[TBL] [Abstract][Full Text] [Related]
9. Concordance of sustained virologic response at weeks 4, 12 and 24 post-treatment of hepatitis c in the era of new oral direct-acting antivirals: A concise review.
Burgess SV; Hussaini T; Yoshida EM
Ann Hepatol; 2016; 15(2):154-9. PubMed ID: 26845592
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure.
Lu M; Wu KH; Li J; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Daida YG; Schmidt MA; Rupp LB; Zhang T; Trudeau S; Gordon SC
J Viral Hepat; 2019 Oct; 26(10):1210-1217. PubMed ID: 31197910
[TBL] [Abstract][Full Text] [Related]
11. A 12-week rescue therapy by PrOD-based regimen for advanced fibrotic genotype-1 CHC patients who failed to pegylated interferon plus ribavirin.
Wu SH; Chu CJ; Lin CC; Su CW; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC
J Chin Med Assoc; 2019 Mar; 82(3):186-190. PubMed ID: 30908411
[TBL] [Abstract][Full Text] [Related]
12. Rapid hepatitis C virus clearance by antivirals correlates with immune status of infected patients.
Sasaki R; Meyer K; Moriyama M; Kato N; Yokosuka O; Ray RB; Aurora R; Ray R; Kanda T
J Med Virol; 2019 Mar; 91(3):411-418. PubMed ID: 30192392
[TBL] [Abstract][Full Text] [Related]
13. HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients.
Rockstroh JK; Feld JJ; Chevaliez S; Cheng K; Wedemeyer H; Sarrazin C; Maasoumy B; Herman C; Hackett J; Cohen DE; Dawson GJ; Cloherty G; Pawlotsky JM
J Virol Methods; 2017 Jul; 245():14-18. PubMed ID: 28359920
[TBL] [Abstract][Full Text] [Related]
14. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome.
Meissner EG; Wu D; Osinusi A; Bon D; Virtaneva K; Sturdevant D; Porcella S; Wang H; Herrmann E; McHutchison J; Suffredini AF; Polis M; Hewitt S; Prokunina-Olsson L; Masur H; Fauci AS; Kottilil S
J Clin Invest; 2014 Aug; 124(8):3352-63. PubMed ID: 24983321
[TBL] [Abstract][Full Text] [Related]
15. IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses.
Han JW; Sung PS; Hong SH; Lee H; Koh JY; Lee H; White S; Maslow JN; Weiner DB; Park SH; Jeong M; Heo J; Ahn SH; Shin EC
J Hepatol; 2020 Jul; 73(1):72-83. PubMed ID: 32088322
[TBL] [Abstract][Full Text] [Related]
16. Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During Direct-Acting Antiviral Therapy.
Alao H; Cam M; Keembiyehetty C; Zhang F; Serti E; Suarez D; Park H; Fourie NH; Wright EC; Henderson WA; Li Q; Liang TJ; Rehermann B; Ghany MG
Hepatology; 2018 Dec; 68(6):2078-2088. PubMed ID: 29704252
[TBL] [Abstract][Full Text] [Related]
17. Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents.
Huang SC; Cheng PN; Liu CH; Yang HC; Su TH; Tseng TC; Chen PJ; Kao JH; Liu CJ
J Formos Med Assoc; 2022 May; 121(5):920-929. PubMed ID: 34538552
[TBL] [Abstract][Full Text] [Related]
18. Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia.
Maduell F; Belmar L; Ugalde J; Laguno M; Martínez-Rebollar M; Ojeda R; Arias M; Rodas L; Rossi F; Llovet LP; González LN; Mallolas J; Londoño MC
Gastroenterol Hepatol; 2019 Mar; 42(3):164-170. PubMed ID: 30293914
[TBL] [Abstract][Full Text] [Related]
19. Decreased expression of interferon-stimulated genes in B cells of patients with chronic hepatitis C during interferon-free therapy potentially suggests the eradication of hepatitis C virus in the B cells: A cohort study.
Arai J; Ito T; Shimozuma Y; Uchikoshi M; Nakajima Y; Sakaki M; Uozumi S; Kajiwara A; Sugiura I; Otoyama Y; Nozawa H; Kurihara T; Eguchi J; Nomura N; Sakuma D; Sato M; Deguchi Y; Yoshida H
Health Sci Rep; 2020 Sep; 3(3):e176. PubMed ID: 32685701
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic hepatitis C virus infection.
Hou J; van Oord G; Groothuismink ZM; Claassen MA; Kreefft K; Zaaraoui-Boutahar F; van IJcken WF; Osterhaus AD; Janssen HL; Andeweg AC; de Knegt RJ; Boonstra A
J Virol; 2014 Nov; 88(21):12254-64. PubMed ID: 25100847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
